

Andrea Rubboli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1752643/publications.pdf>

Version: 2024-02-01

47
papers

1,360
citations

430442

18
h-index

344852

36
g-index

48
all docs

48
docs citations

48
times ranked

2300
citing authors

#	ARTICLE	IF	CITATIONS
1	Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care. <i>European Heart Journal</i> , 2011, 32, 1723-1731.	0.7	209
2	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011, 13, 723-746.	0.7	197
3	Antithrombotic management in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci3n Cardíaca y. <i>Europace</i> , 2017, 19, 1757-1758.	0.7	107
4	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	1.0	106
5	One-Year Outcome of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: An Analysis of the <sc>AFCAS</sc> Registry. <i>Clinical Cardiology</i> , 2014, 37, 357-364.	0.7	85
6	Meta-Analysis of Randomized Controlled Trials and Adjusted Observational Results of Use of Clopidogrel, Aspirin, and Oral Anticoagulants in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2015, 115, 1185-1193.	0.7	65
7	Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. <i>World Journal of Cardiology</i> , 2011, 3, 351.	0.5	60
8	CHADS 2 , CHA 2 DS 2 -VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2014, 133, 560-566.	0.8	58
9	Periprocedural Management and In-Hospital Outcome of Patients with Indication for Oral Anticoagulation Undergoing Coronary Artery Stenting. <i>Journal of Interventional Cardiology</i> , 2009, 22, 390-397.	0.5	53
10	Heparin Bridging vs. Uninterrupted Oral Anticoagulation in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting. <i>Circulation Journal</i> , 2012, 76, 1363-1368.	0.7	42
11	Antithrombotic Management and 1-Year Outcome of Patients on Oral Anticoagulation Undergoing Coronary Stent Implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry). <i>American Journal of Cardiology</i> , 2012, 109, 1411-1417.	0.7	30
12	Performance of Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 113, 1995-2001.	0.7	26
13	Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. <i>Journal of Invasive Cardiology</i> , 2014, 26, 563-9.	0.4	24
14	Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1325-1332.	0.9	23
15	Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E12-22.	0.7	22
16	Bare-Metal vs. Drug-Eluting Stents in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2014, 78, 2674-2681.	0.7	21
17	New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. <i>International Journal of Cardiology</i> , 2015, 196, 133-138.	0.8	19
18	Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry. <i>American Heart Journal</i> , 2017, 190, 86-93.	1.2	19

#	ARTICLE	IF	CITATIONS
19	Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: The AFCAS study. <i>International Journal of Cardiology</i> , 2015, 183, 105-110.	0.8	17
20	Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>BMJ Open</i> , 2014, 4, e004700.	0.8	15
21	The Management of Patients on Oral Anticoagulation Undergoing Coronary Stent Implantation: A Survey among Interventional Cardiologists from Eight European Countries. <i>Journal of Interventional Cardiology</i> , 2012, 25, 163-169.	0.5	14
22	Coronary Stent Implantation in Patients Committed to Long-term Oral Anticoagulation Therapy. <i>Chest</i> , 2011, 139, 981-987.	0.4	13
23	What is the Role for Glycoprotein IIB/IIIa Inhibitor Use in the Catheterization Laboratory in the Current Era?. <i>Current Vascular Pharmacology</i> , 2018, 16, 451-458.	0.8	12
24	Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 264-271.	0.6	12
25	Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 425-430.	0.3	11
26	A prospective multicentre observational study on the management of patients on oral anticoagulation undergoing coronary artery stenting: rationale and design of the ongoing warfarin and coronary stenting (WAR-STENT) registry. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 200-203.	0.6	10
27	Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?. <i>Internal and Emergency Medicine</i> , 2013, 8, 673-680.	1.0	10
28	Adherence to and persistence with non-vitamin K-antagonist oral anticoagulants: does the number of pills per day matter?. <i>Current Medical Research and Opinion</i> , 2015, 31, 1845-1847.	0.9	10
29	Bivalirudin use during percutaneous coronary intervention in patients on chronic warfarin therapy. <i>Thrombosis Research</i> , 2014, 133, 695-696.	0.8	8
30	Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial. <i>PLoS ONE</i> , 2015, 10, e0128492.	1.1	8
31	Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , 2017, 34, 620-637.	1.3	8
32	The risk of bleeding of triple therapy with vitamin K-antagonists, aspirin and clopidogrel after coronary stent implantation: Facts and questions. <i>Journal of Geriatric Cardiology</i> , 2012, 8, 207-214.	0.2	7
33	Value of DAPT score to predict adverse outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: A post-hoc analysis from the AFCAS registry. <i>International Journal of Cardiology</i> , 2018, 253, 35-39.	0.8	7
34	The antithrombotic management of patients on oral anticoagulation undergoing coronary stent implantation: an update. <i>Internal and Emergency Medicine</i> , 2012, 7, 299-304.	1.0	4
35	New-onset atrial fibrillation after percutaneous coronary intervention with stent: Updated proposal of an algorithm for the choice of oral anticoagulant and its dose. <i>European Journal of Internal Medicine</i> , 2017, 40, e11-e12.	1.0	4
36	Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>Clinical Research in Cardiology</i> , 2017, 106, 420-427.	1.5	4

#	ARTICLE	IF	CITATIONS
37	Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug?. <i>European Journal of Internal Medicine</i> , 2017, 46, e40-e41.	1.0	4
38	What is the significance, if any, of the increased incidence of stent thrombosis with dual therapy of dabigatran 110 mg twice daily and clopidogrel in the RE-DUAL PCI trial?. <i>European Journal of Internal Medicine</i> , 2018, 50, e27-e28.	1.0	4
39	Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism. <i>International Journal of Cardiology</i> , 2018, 269, 75-79.	0.8	4
40	Anti-platelet pre-treatment for atrial fibrillation patients on warfarin referred for coronary angiography/stenting because of non-ST-elevation acute coronary syndrome: An alternative proposal. <i>International Journal of Cardiology</i> , 2015, 201, 494-496.	0.8	3
41	Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. <i>Clinical Cardiology</i> , 2017, 40, 1264-1270.	0.7	2
42	Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 520-521.	0.6	1
43	Reduced dose and reduced exposure to non-vitamin K-antagonist oral anticoagulants: Some considerations on this relationship. <i>International Journal of Cardiology</i> , 2016, 223, 519-520.	0.8	1
44	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Suggested strategies tailored to an integrated evaluation of different risk profiles. <i>European Journal of Internal Medicine</i> , 2017, 41, e10-e11.	1.0	1
45	Oral anticoagulation alone for concomitant stable coronary artery disease and atrial fibrillation: A definitive strategy?. <i>International Journal of Cardiology</i> , 2018, 264, 95-96.	0.8	0
46	Changes in antithrombotic therapy after a cerebrovascular or coronary ischemic event in the WARfarin and coronary STENTing (WAR-STENT) registry. <i>Panminerva Medica</i> , 2016, 58, 242-3.	0.2	0
47	IN-HOSPITAL antithrombotic therapy and outcomes of ELDERLY patients on warfarin undergoing percutaneous coronary intervention: Insights from the WAR-STENT registry. <i>Indian Heart Journal</i> , 2022, , .	0.2	0